Key result
Preexisting dual antiplatelet treatment before thrombolysis for acute ischemic stroke increased the risk of symptomatic intracerebral hemorrhage (14.3% per SITS-MOST) compared to no antiplatelet use.
Why the study?
Does preexisting dual antiplatelet therapy increase the risk of symptomatic intracerebral hemorrhage in Chinese acute ischemic stroke patients receiving intravenous thrombolysis?
Cohort
Yes
Does preexisting dual antiplatelet therapy increase the risk of symptomatic intracerebral hemorrhage in Chinese acute ischemic stroke patients receiving intravenous thrombolysis?
Preexisting dual antiplatelet therapy, but not aspirin alone, is associated with an increased risk of symptomatic intracranial hemorrhage following intravenous thrombolysis for acute ischemic stroke.
No takes yet. Share an insight, caveat, or question.
May warrant caution with dual antiplatelet before thrombolysis; extends observational data but leaves open need for randomized confirmation.
Pan et al. (2014) conducted a cohort in Acute ischemic stroke. Preexisting dual antiplatelet treatment vs. No antiplatelet treatment was evaluated on Symptomatic intracerebral hemorrhage (sICH) per SITS-MOST criteria. Preexisting dual antiplatelet treatment before thrombolysis for acute ischemic stroke increased the risk of symptomatic intracerebral hemorrhage (14.3% per SITS-MOST) compared to no antiplatelet use.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: